Investigating new treatments for cancer by targeting gene regulation mechanisms.
Official title: Allosteric Modulators of Polycomb Repressive 2 Gene Repression as Potential Therapeutics for the Development of Novel Epigenetic Cancer Therapies
Funded at Brooklyn College · NIH-10810634 · Data updated 2026-11-12
This study is exploring new cancer treatments that target a specific protein complex called PRC2, which is involved in how genes are controlled, with the hope of creating better therapies for patients to improve their chances of recovery and lower the risk of cancer coming back.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Brooklyn College NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | April 1, 2020 |
| Project end | March 31, 2026 |
| Funding year | 2024 |
| Award (this year) | $392,500 |
| NIH project number | 5SC1GM136635-04 |
| Project ID | NIH-10810634 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with cancers associated with PRC2 overactivity.
✕Less likely to help
Patients with cancers not linked to PRC2 dysregulation may not benefit from this research.
What this research studies
This research focuses on developing new anticancer therapies that target the polycomb repressive complex 2 (PRC2), which plays a crucial role in gene regulation through epigenetic modifications. By understanding how PRC2 contributes to cancer development, the researchers aim to create allosteric modulators that can effectively inhibit its function. The approach involves studying the mechanisms of PRC2 and its components, particularly in relation to their overexpression in various cancers. Patients may benefit from potential new treatments that could improve outcomes and reduce the risk of cancer recurrence.
Why it matters
Potential benefit: If successful, this research could lead to innovative cancer therapies that improve survival rates and quality of life for patients.
How similar studies have gone: Previous research has shown promise in targeting PRC2, but this approach aims to develop novel inhibitors that have not yet been tested.
Where this research is happening
-
Brooklyn College
New York, United States Active
Researchers
- Principal investigator: Gerona-Navarro, Guillermo — Brooklyn College
- Study coordinator: Gerona-Navarro, Guillermo
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.